A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 47/48 (2006.01) A61K 38/17 (2006.01) C07K 14/47 (2006.01) C07K 14/54 (2006.01) C07K 14/575 (2006.01) C07K 14/61 (2006.01) C07K 14/62 (2006.01) C07K 16/28 (2006.01) C07K 16/42 (2006.01)
Patent
CA 2424730
Disclosed herein are complexes and compounds that pass through cellular barriers to deliver compounds into, through and out of cells, and methods of producing and using such complexes and compounds. The complexes and compounds of the invention comprise a biologically active portion and a targeting element directed to a ligand that confers transcellular, transcytotic or paracellular transporting properties to an agent specifically bound to the ligand, with the proviso that the targeting element is not an antibody. Also disclosed are complexes and compounds that comprise two or more targeting elements directed to a ligand that confers transcellular, transcytotic or paracellular transporting properties to an agent specifically bound to the ligand. Preferred ligands include but are not limited to the stalk of pIgR, a pIgR domain, an amino acid sequence that is conserved among pIgR's from different animals, and one of several regions of pIgR defined herein.
L'invention concerne des complexes et des composés traversant les barrières cellulaires pour la fourniture intra-, trans- et extracellulaire de substances, et des procédés relatifs à l'élaboration et à l'utilisation des complexes et des composés en question. Lesdits complexes et composés renferment une partie biologiquement active et un élément de ciblage orienté vers un ligand qui confère des propriétés de transport transcellulaire, transcytose ou paracellulaire à un agent spécifiquement lié au ligand, à condition que l'élément de ciblage ne soit pas un anticorps. L'invention concerne également des complexes et des composés renfermant deux ou plus de deux éléments de ciblage orientés vers un ligand qui confèrent des propriétés de transport transcellulaire, transcytose ou paracellulaire à un agent spécifiquement lié au ligand. De préférence, les ligands sont déterminés comme suit, mais pas exclusivement: tige de pIgR, domaine pIgR, séquence d'acides aminés conservée à partir des pIgR de différents animaux, et une ou plusieurs zones de pIgR définies à l'intérieur de ce type de structure.
Chapin Steven
Glynn Jacqueline M.
Hawley Stephen
Houston L.l.
Sheridan Philip L.
Arizeke Pharmaceuticals Inc.
Gowling Lafleur Henderson Llp
LandOfFree
Compositions and methods for the transport of biologically... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the transport of biologically..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the transport of biologically... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1625464